PMID- 35078225
OWN - NLM
STAT- MEDLINE
DCOM- 20221010
LR  - 20221017
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 61
IP  - 10
DP  - 2022 Oct 6
TI  - Rates and predictors of methotrexate-related adverse events in patients with 
      early rheumatoid arthritis: results from a nationwide UK study.
PG  - 3930-3938
LID - 10.1093/rheumatology/keab917 [doi]
AB  - OBJECTIVES: To estimate prevalence rates and identify baseline predictors of 
      adverse events (AEs) over the first year of treatment in patients with RA 
      starting MTX. METHODS: Data came from the UK Rheumatoid Arthritis Medication 
      Study (RAMS), a prospective cohort of patients with RA starting MTX. This 
      analysis included patients aged >/=18 years with physician diagnosed RA and symptom 
      duration </=2 years, who were commencing MTX for the first time. AEs were recorded 
      by interviewing patients at 6- and 12-month follow-up visits. The period 
      prevalence rates of AEs are reported for 0-6 months, 6-12 months and 0-12 months 
      of follow-up. The associations between baseline characteristics and AEs were 
      assessed using multivariable logistic regression. RESULTS: A total of 1069 
      patients were included in the analysis. Overall, 77.5% experienced at least one 
      AE. The most commonly reported AEs were: gastrointestinal (42.0%), neurological 
      (28.6%), mucocutaneous (26.0%), pulmonary (20.9%), elevated alanine transaminase 
      (18.0%) and haematological AEs (5.6%). Factors associated with increased odds of 
      AEs were: women vs men (gastrointestinal, mucocutaneous, neurological) and 
      alcohol consumption (nausea, alopecia, mucocutaneous). Older age, higher 
      estimated glomerular filtration rate and alcohol consumption were associated with 
      less reporting of haematological AEs. CONCLUSIONS: AEs were common among patients 
      over the first year of MTX, although most were not serious. Knowledge of the 
      rates and factors associated with AE occurrence are valuable when communicating 
      risks prior to commencing MTX. This can help patients make informed decisions 
      whether to start MTX, potentially increasing adherence to treatment.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology.
FAU - Sherbini, Ahmad A
AU  - Sherbini AA
AUID- ORCID: 0000-0002-7554-0752
AD  - Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, 
      Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, 
      Medicine and Health, The University of Manchester.
FAU - Gwinnutt, James M
AU  - Gwinnutt JM
AUID- ORCID: 0000-0002-1435-8797
AD  - Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, 
      Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, 
      Medicine and Health, The University of Manchester.
FAU - Hyrich, Kimme L
AU  - Hyrich KL
AUID- ORCID: 0000-0001-8242-9262
AD  - Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, 
      Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, 
      Medicine and Health, The University of Manchester.
AD  - NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation 
      Trust, Manchester Academic Health Science Centre, Manchester, UK.
CN  - RAMS Co-Investigators
FAU - Verstappen, Suzanne M M
AU  - Verstappen SMM
AD  - Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, 
      Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, 
      Medicine and Health, The University of Manchester.
AD  - NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation 
      Trust, Manchester Academic Health Science Centre, Manchester, UK.
LA  - eng
GR  - 20385/VAC_/Versus Arthritis/United Kingdom
GR  - 20380/VAC_/Versus Arthritis/United Kingdom
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antirheumatic Agents)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Alanine Transaminase
MH  - Animals
MH  - *Antirheumatic Agents/adverse effects
MH  - *Arthritis, Rheumatoid/chemically induced/drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Male
MH  - Methotrexate/adverse effects
MH  - Prospective Studies
MH  - Sheep
MH  - Treatment Outcome
MH  - United Kingdom/epidemiology
PMC - PMC9536779
OTO - NOTNLM
OT  - DMARDs
OT  - adverse events
OT  - methotrexate
OT  - prognostic factors
OT  - rheumatoid arthritis
FIR - Adebajo, Ade
IR  - Adebajo A
FIR - Ahmed, Khalid
IR  - Ahmed K
FIR - Al-Ansari, Atheer
IR  - Al-Ansari A
FIR - Amarasena, Roshan
IR  - Amarasena R
FIR - Bukhari, Marwan
IR  - Bukhari M
FIR - Callan, Margaret
IR  - Callan M
FIR - Chelliah, Easwaradhas G
IR  - Chelliah EG
FIR - Chinoy, Hector
IR  - Chinoy H
FIR - Cooper, Annie
IR  - Cooper A
FIR - Dasgupta, Bhaskar
IR  - Dasgupta B
FIR - Davis, Martin
IR  - Davis M
FIR - Galloway, James
IR  - Galloway J
FIR - Gough, Andrew
IR  - Gough A
FIR - Green, Michael
IR  - Green M
FIR - Gullick, Nicola
IR  - Gullick N
FIR - Hamilton, Jennifer
IR  - Hamilton J
FIR - Hassan, Waji
IR  - Hassan W
FIR - Hider, Samantha
IR  - Hider S
FIR - Hyrich, Kimme
IR  - Hyrich K
FIR - Kamath, Sanjeet
IR  - Kamath S
FIR - Knight, Susan
IR  - Knight S
FIR - Lane, Suzanne
IR  - Lane S
FIR - Lee, Martin
IR  - Lee M
FIR - Levy, Sarah
IR  - Levy S
FIR - Macphie, Lizzy
IR  - Macphie L
FIR - Marguerie, Christopher
IR  - Marguerie C
FIR - Marshall, Tarnya
IR  - Marshall T
FIR - Mathews, Catherine
IR  - Mathews C
FIR - McKenna, Frank
IR  - McKenna F
FIR - Naz, Sophia
IR  - Naz S
FIR - Perry, Mark
IR  - Perry M
FIR - Pollard, Louise
IR  - Pollard L
FIR - Quilty, Brian
IR  - Quilty B
FIR - Robertson, Lindsay
IR  - Robertson L
FIR - Roy, Dipak
IR  - Roy D
FIR - Sanders, Paul
IR  - Sanders P
FIR - Saravanan, Vadivelu
IR  - Saravanan V
FIR - Scott, David
IR  - Scott D
FIR - Smith, Gillian
IR  - Smith G
FIR - Smith, Richard
IR  - Smith R
FIR - Symmons, Deborah
IR  - Symmons D
FIR - Teh, Lee-Suan
IR  - Teh LS
FIR - Viner, Nick
IR  - Viner N
EDAT- 2022/01/26 06:00
MHDA- 2022/10/12 06:00
PMCR- 2022/01/25
CRDT- 2022/01/25 20:18
PHST- 2021/08/16 00:00 [received]
PHST- 2021/12/05 00:00 [revised]
PHST- 2022/01/26 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/01/25 20:18 [entrez]
PHST- 2022/01/25 00:00 [pmc-release]
AID - 6515266 [pii]
AID - keab917 [pii]
AID - 10.1093/rheumatology/keab917 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2022 Oct 6;61(10):3930-3938. doi: 
      10.1093/rheumatology/keab917.